Activities Report and Appendix 4C for June 2021 Quarter
Melbourne (Australia) – 22 July 2021. Telix provides its Appendix 4C and accompanying Activities Report for the quarter ended 30 June 2021.
Telix today provides its Appendix 4C quarterly cash flow statement and accompanying Activities Report for the quarter ended 30 June 2021.
Telix has continued its progress in transitioning to a commercial-stage, revenue generating company. At a macro level, this included the establishment of an Asia-Pacific (APAC) operating region in May, a restructuring of the business designed to support this transition, and the Company’s rapid commercial development.
With interest and activity building in the field of prostate cancer molecularly targeted radiation (MTR) for both diagnostic and therapeutic use, Telix has been working closely with suppliers and distribution partners to ensure that the roll-out of Illuccix®, our first commercial product, is delivered seamlessly and without delay, subject to requisite regulatory approvals worldwide.
Telix CEO Dr. Chris Behrenbruch stated, “We continue to make significant progress in a number of areas across the business, in preparation for commercial launch and towards our clinical and developmental milestones. As we anticipate FDA approval for our first commercial product Illuccix® Telix has demonstrated that our supply chain and distribution model has us positioned advantageously to move quickly to drive market adoption post-launch. The acceleration in recruitment of our ZIRCON trial after a period of unpredictability ensures we remain on track to complete the study this year and commence preparations for launch of our second commercial product.”
To view the full Appendix 4C and Activities Report please click here .
To return to Telix’s homepage please click here.